Expert Perspectives

Getting It Right First Time – GIRFT and Sequencing

Hear from Dr Keith Wu as he uses real-world data and case studies in a presentation that addresses the key concepts of biological sequencing in psoriasis management, the potential costs of biologic failure, and the importance of ‘getting it right first time’ both for patients and for the NHS.

Getting It Right First Time – GIRFT and Sequencing

Hear from Dr Keith Wu as he uses real-world data and case studies in a presentation that addresses the key concepts of biological sequencing in psoriasis management, the potential costs of biologic failure, and the importance of ‘getting it right first time’ both for patients and for the NHS.

UK-RISN-250110. Date of preparation June 2025.

HORIZONS is a series of events and resources for healthcare professionals involved in the management of patients with psoriasis, through which experts share their insights and explore the dynamic psoriasis treatment landscape.

Treat to Target

Expert discussion on the importance of assessing the impact of psoriasis on patients’ quality of life and defining treatment goals tailored to their needs and lifestyles, with Dr Sandy McBride and Hannah Lakin.

Evolution of psoriasis management

Watch Dr Andrew Pink describe how the evolution of treatment options for patients with psoriasis means many patients today can expect to achieve clear/nearly clear skin within a year of treatment initiation. His comprehensive review summarises key supporting data and real-world evidence on available biologics and small molecule inhibitors.

In for the long run – the importance of durability in psoriasis management

Aiming for clear skin has the potential to improve patient quality of life. Dr Laura Savage explores the data on SKYRIZI, including the findings of the VALUE study, that highlight the importance of achieving durable responses and why long-term effectiveness matters to patients.

Getting It Right First Time – GIRFT and Sequencing

Hear from Dr Keith Wu as he uses real-world data and case studies in a presentation that addresses the key concepts of biological sequencing in psoriasis management, the potential costs of biologic failure, and the importance of ‘getting it right first time’ both for patients and for the NHS.

Reflecting on Horizons - Dr Keith Wu

Dr Keith Wu discusses the value of getting psoriasis treatment right the first time, highlighting that early use of biologics can reduce disease burden and improve NHS efficiency. He highlights how meetings like Horizons help clinicians stay up to date on evolving treatment pathways.

The Psoriasis Patient Journey & Optimising Outcomes

Watch an insightful discussion between consultant dermatologists Professor Jonathan Barker and Dr Andrew Pink on aiming to provide optimal care for patients with psoriasis in the post-pandemic era, including how therapy innovation has opened doors for more flexible, patient-centric care.

Skin of Colour

Expert commentary on the importance of understanding how inflammatory skin conditions present in skin of colour, with Dr Laura Savage and Dr Mary Sommerlad.

The Getting Under the Skin with SKYRIZI series illustrates, through diverse case studies, psoriasis patient experiences and provides clarity on how therapy can be tailored to their specific treatment goals and lifestyle needs. Watch to discover the real-life impact of SKYRIZI on patients’ lives.

The Family Man Revisited

Look back at the story of a 65-year-old man, who over 3 years ago recovered from severe mental distress after achieving sustained skin clearance with SKYRIZI and can now reclaim the life he wants with fewer clinic appointments.

The Travelling TV Producer Revisited

Revisit the story of a TV producer who, after achieving skin and nail clearance over 3 years ago with SKYRIZI aged 32, no longer needs frequent clinic visits, has regained her confidence, and is thriving in her career and new relationship.

The Psoriasis Patient with Comorbidities Revisited

Journey back and see how a 53-year-old male with multiple comorbidities and chronic plaque psoriasis since 1981 achieved skin clearance with SKYRIZI for over 3 years, allowing him to pursue his interests without the disruption of frequent clinic visits.

The Young Footballer Revisited

Revisit the story of the 29-year-old footballer who achieved full clearance of his long-standing facial and scalp psoriasis with SKYRIZI, and who, more than 3 years later, continues to thrive in his personal life, no longer hiding his face.

Dressed for Winter in Summer Revisited

Rediscover how skin clearance with SKYRIZI over 4 years ago allowed a 34-year-old female patient to build her confidence, completely abstain from alcohol and finally feel free to choose what she wants to wear in the summer.

The 78-Year-old Man Revisited

Rediscover the story of a 78-year-old man with a history of psoriasis since the age of 30 who regained optimism after achieving skin clearance with SKYRIZI over 3 years ago, allowing him to finally focus on his broader holistic needs.

The York Experience

Dr Keith Wu and Pauline Stopford- Taylor revisit their experience setting up a specialist service in York. They also illustrate the convenience in dosing and impact of SKYRIZI by sharing their treatment journey with a patient whose psoriasis of the hands was affecting his ability to act as a primary carer for his wife.

Hear from leading experts who provide their take on SKYRIZI’s efficacy data, real-world use, dosing regimen, safety profile, and associated healthcare resources.

Skyrizi in Psoriatic Arthritis

Dr Laura Savage discusses the results of KEEPsAKE1 and 2 clinical trials.

Get to grips with the basics behind SKYRIZI with fundamental educational content on the therapy.

How SKYRIZI (risankizumab) works differently

Explaining how SKYRIZI works and it’s differences versus other IL-classes using a garden analogy.

SKYRIZI (risankizumab) PFS Training Video

UK Skyrizi 150mg PFS Injection Training.

How SKYRIZI (risankizumab) works

In under 2 minutes, Dr Laura Savage explains how SKYRIZI inhibits the IL-12/Th17 pathway using a spilt milk carton analogy.

SKYRIZI (risankizumab) PFP Training Video

UK Skyrizi 150mg PFP Injection Training.

References

Reich K, et al. Lancet 2019; 394: 576-586.
Gordon KB, et al. Lancet 2018; 392: 650-661.
Warren RB, et al. Br J Dermatol 2021;184:50-59
SKYRIZI Summary of Product Characteristics.

UK-RISN-260055. Date of preparation: July 2026.

SKYRIZI PRESCRIBING INFORMATION
ADALIMUMAB PRESCRIBING INFORMATION

Important safety information for SKYRIZI^®(risankizumab) in Psoriasis and Psoriatic Arthritis¹
SKYRIZI should be initiated and supervised by healthcare professionals experienced in the diagnosis and treatment of Psoriasis and Psoriatic arthritis.

Some patients may not be suitable for SKYRIZI (risankizumab). You are strongly advised to read the prescribing information, which can be found at the top of this webpage and below, and the Summary of Product Characteristics (SmPC) which are available online in the Electronic Medicines Compendium (EMC) from the links below.

SKYRIZI 150 mg solution for injection in pre-filled pen CLICK HERE.
SKYRIZI 150 mg solution for injection in pre-filled syringe CLICK HERE.

SKYRIZI PRESCRIBING INFORMATION CLICK HERE.

SKYRIZI is contraindicated in patients;

with hypersensitivity to the active substance or to any of the excipients,
with clinically important active infections (e.g. active tuberculosis).

Cautions (See Prescribing Information and SmPC for full details including screening and monitoring requirements):
It is preferable to avoid the use of SKYRIZI during pregnancy. Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment. It is unknown whether risankizumab is excreted in human milk. A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.

Dosing in Psoriasis and Psoriatic Arthritis
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.

Adverse reactions
For adverse reactions, please refer to the prescribing information and the SKYRIZI summary of product characteristics available online in the Electronic Medicines Compendium via the links above.

Important safety information for HUMIRA^® (adalimumab) in Psoriasis and Psoriatic Arthritis²
HUMIRA is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which HUMIRA is indicated.

Psoriatic arthritis: HUMIRA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. HUMIRA has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.
Psoriasis: HUMIRA is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who are candidates for systematic therapy

Paediatric plaque psoriasis: HUMIRA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

Some patients may not be suitable for HUMIRA. You are strongly advised to read the prescribing information, which can be found at the top of this webpage and below, and the Summary of Product Characteristics (SmPC) which are available online in the Electronic Medicines Compendium (EMC).

HUMIRA 40 mg solution for injection in pre-filled pen CLICK HERE.

ADALIMUMAB PRESCRIBING INFORMATION CLICK HERE.

References
1. SKYRIZI Summary of Product Characteristics
2. HUMIRA Summary of Product Characteristics

Expert Perspectives

References

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome